Synopsis
Synopsis
0
CEP/COS
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Europe
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
Annual Reports
NA
Regulatory FDF Prices
NA
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. C.m.9155
2. Env905
3. Epitopic
1. 23674-86-4
2. Durezol
3. Dfba
4. Myser
5. Epitopic
6. [(6s,8s,9r,10s,11s,13s,14s,17r)-17-(2-acetyloxyacetyl)-6,9-difluoro-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] Butanoate
7. Difluoroprednisolone Butyrate Acetate
8. W 6309
9. Cm 9155
10. S8a06qg2qe
11. Difluprednatum
12. Mls000028663
13. Mls001148580
14. Chebi:31485
15. W-6309
16. Smr000058924
17. (6alpha,11beta)-21-(acetyloxy)-6,9-difluoro-11-hydroxy-17-(1-oxobutoxy)pregna-1,4-diene-3,20-dion
18. Difluprednato
19. 6alpha,9alpha-difluoroprednisolone 21-acetate 17-butyrate
20. Durezol (tn)
21. Unii-s8a06qg2qe
22. Difluprednatum [inn-latin]
23. Difluprednato [inn-spanish]
24. Difluprednate [usan:inn:jan]
25. Ncgc00168749-01
26. Einecs 245-815-4
27. Mfcd00214273
28. Opera_id_1287
29. Difluprednate [mi]
30. Difluprednate [inn]
31. Difluprednate [jan]
32. Schembl4580
33. Difluprednate [usan]
34. Dsstox_cid_26773
35. Dsstox_rid_81894
36. Dsstox_gsid_46773
37. Difluprednate [vandf]
38. Mls001333701
39. St60-1
40. Difluprednate [mart.]
41. Difluprednate [who-dd]
42. Gtpl7474
43. Chembl1201749
44. Difluprednate (jan/usan/inn)
45. Dtxsid0046773
46. 6-alpha,9-alpha-difluoroprednisolone 17-butyrate 21-acetate
47. Hms2231d18
48. Difluprednate [orange Book]
49. (6s,8s,9r,10s,11s,13s,14s,17r)-17-(2-acetoxyacetyl)-6,9-difluoro-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3h-cyclopenta[a]phenanthren-17-yl Butyrate
50. Act03289
51. Zinc4212945
52. Tox21_112628
53. S4095
54. Ccg-269762
55. Db06781
56. 6alpha,9-difluoro-11beta,17,21-trihydroxypregna-1,4-diene-3,20-dione 21-acetate 17-butyrate
57. 21-(acetyloxy)-6,9-difluoro-11-hydroxy-17-(1-oxobutoxy)pregna-1,4-diene-3,20-dione (6alpha,11beta)-
58. As-15800
59. Hy-17569
60. Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-6,9-difluoro-11-hydroxy-17-(1-oxobutoxy)-, (6.alpha.,11.beta.)-
61. Cas-23674-86-4
62. D5579
63. D01266
64. Ab00383058_10
65. 674d864
66. A932746
67. Q736113
68. Sr-01000000265
69. Q-101389
70. Sr-01000000265-4
71. 6alpha-9-difluoroprednisolone 21-acetate 17-butyrate
72. 6 Alpha ,9 Alpha -difluoroprednisolone 21-acetate 17-butyrate
73. 6alpha,9alpha-difluoroprednisolone 21-acetate 17-butyrate, >=98%
74. (1r,2s,8s,10s,11s,14r,15s,17s)-14-[2-(acetyloxy)acetyl]-1,8-difluoro-17-hydroxy-2,15-dimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-dien-14-yl Butanoate
75. 6.alpha.,9-difluoro-11.beta.,17,21-trihydroxypregna-1,4-diene-3,20-dione 21-acetate 17-butyrate
76. Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-6,9-difluoro-11-hydroxy-17-(1-oxobutoxy)-, (6alpha,11beta)-
77. Pregna-1,4-diene-3,20-dione, 6-alpha,9-difluoro-11-beta,17,21-trihydroxy-, 21-acetate, 17-butyrate
78. Pregna-1,4-diene-3,20-dione,21-(acetyloxy)-6,9-difluoro-11-hydroxy-17-(1-oxobutoxy)-, (6a,11b)-
| Molecular Weight | 508.5 g/mol |
|---|---|
| Molecular Formula | C27H34F2O7 |
| XLogP3 | 3.4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 8 |
| Exact Mass | 508.22725974 g/mol |
| Monoisotopic Mass | 508.22725974 g/mol |
| Topological Polar Surface Area | 107 Ų |
| Heavy Atom Count | 36 |
| Formal Charge | 0 |
| Complexity | 1050 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 8 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 2 | |
|---|---|
| Drug Name | Durezol |
| PubMed Health | Difluprednate (Into the eye) |
| Drug Classes | Anti-Inflammatory |
| Drug Label | Durezol (difluprednate ophthalmic emulsion) 0.05% is a sterile, topical anti-inflammatory corticosteroid for ophthalmic use. The chemical name is 6,9difluoro-11,17,21-trihydroxypregna-1,4-diene-3,20-dione 21-acetate 17-butyrate (CAS number 23674-... |
| Active Ingredient | Difluprednate |
| Dosage Form | Emulsion |
| Route | Ophthalmic |
| Strength | 0.05% |
| Market Status | Prescription |
| Company | Alcon Pharms |
| 2 of 2 | |
|---|---|
| Drug Name | Durezol |
| PubMed Health | Difluprednate (Into the eye) |
| Drug Classes | Anti-Inflammatory |
| Drug Label | Durezol (difluprednate ophthalmic emulsion) 0.05% is a sterile, topical anti-inflammatory corticosteroid for ophthalmic use. The chemical name is 6,9difluoro-11,17,21-trihydroxypregna-1,4-diene-3,20-dione 21-acetate 17-butyrate (CAS number 23674-... |
| Active Ingredient | Difluprednate |
| Dosage Form | Emulsion |
| Route | Ophthalmic |
| Strength | 0.05% |
| Market Status | Prescription |
| Company | Alcon Pharms |
For the treatment of inflammation and pain associated with ocular surgery.
FDA Label
Difluprednate is a corticosteroid used as an anti-inflammatory steroidal drug used primarily in ocular surgery.
Glucocorticoids
A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. (See all compounds classified as Glucocorticoids.)
D - Dermatologicals
D07 - Corticosteroids, dermatological preparations
D07A - Corticosteroids, plain
D07AC - Corticosteroids, potent (group iii)
D07AC19 - Difluprednate
Absorption
Difluprednate penetrates the corneal epithelium rapidly and effectively. Low systemic absorption.
Route of Elimination
78.5% of radioactivity was excreted aftert 24 hours, and 99.5% by 7 days after a single dose of labeled difluprednate instilled in the right eyes of pigmented rabbits.
Difluprednate is rapidly deacetylated in the aqueous humor to difluoroprednisolone butyrate (DFB), the drugs active metabolite. Endogenous tissue esterases then metabolize DFB to the inert metabolite hydroxyfluoroprednisolone butyrate (HFB), which limits systemic exposure to the active compound.
Corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins (lipocortins). It is postulated that these proteins control the biosynthesis of potent mediators of infammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2.
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-08-27
Pay. Date : 2014-04-14
DMF Number : 25228
Submission : 2011-08-23
Status : Active
Type : II
Registration Number : 301MF10046
Registrant's Address : Via Pavia, 1-27027 Gropello Cairoli, Pavia, Italy
Initial Date of Registration : 2019-08-20
Latest Date of Registration :
NDC Package Code : 46439-8738
Start Marketing Date : 2011-07-01
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
| Available Reg Filing : EU |
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
Gonane has API manufacturing expertise in new-age Corticosteroids, Hormones and other pharma raw materials.
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Reviewed
Rev. Date : 2015-10-26
Pay. Date : 2015-10-21
DMF Number : 19870
Submission : 2006-10-16
Status : Active
Type : II
| Available Reg Filing : CA, ASMF |
Human Pharmalabs manufacturer of high quality corticosteroid APIs with a state of the art facility in Kalol Gandhinagar.
NDC Package Code : 46439-8739
Start Marketing Date : 2011-07-01
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT
| Available Reg Filing : EU |
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32778
Submission : 2018-05-10
Status : Active
Type : II
NDC Package Code : 49803-002
Start Marketing Date : 2016-02-03
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (25000g/25000g)
Marketing Category : BULK INGREDIENT

Date of Issue : 2024-11-05
Valid Till : 2027-11-04
Written Confirmation Number : WC-0485
Address of the Firm :


NDC Package Code : 26251-0003
Start Marketing Date : 2017-12-06
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1g/g)
Marketing Category : BULK INGREDIENT

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
GDUFA
DMF Review : Complete
Rev. Date : 2014-08-27
Pay. Date : 2014-04-14
DMF Number : 25228
Submission : 2011-08-23
Status : Active
Type : II
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
GDUFA
DMF Review : Complete
Rev. Date : 2015-10-26
Pay. Date : 2015-10-21
DMF Number : 19870
Submission : 2006-10-16
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 32778
Submission : 2018-05-10
Status : Active
Type : II

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Difluprednate is a topical corticosteroid for inflammation and pain associated with ocular surgery.It is thought to induce phospholipase A2 inhibitory proteins, which controls the biosynthesis of potent mediators of infammation by inhibiting the release of arachidonic acid.
Lead Product(s): Difluprednate,Inapplicable
Therapeutic Area: Neurology Brand Name: Difluprednate-Generic
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 27, 2023
Lead Product(s) : Difluprednate,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Difluprednate is a topical corticosteroid for inflammation and pain associated with ocular surgery.It is thought to induce phospholipase A2 inhibitory proteins, which controls the biosynthesis of potent mediators of infammation by inhibiting the release ...
Product Name : Difluprednate-Generic
Product Type : Steroid
Upfront Cash : Inapplicable
January 27, 2023
Details:
Provectus will use the University’s PDAT medical device with RB-PDT for treating bacterial and parasitic infections of the eye.
Lead Product(s): Rose Bengal Sodium,Difluprednate,Moxifloxacin
Therapeutic Area: Infections and Infectious Diseases Brand Name: RB-PDT
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Provectus Biopharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 27, 2024

Lead Product(s) : Rose Bengal Sodium,Difluprednate,Moxifloxacin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Provectus Biopharmaceuticals
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Provectus Biopharmaceuticals Announces License Agreement for Antimicrobial Treatment
Details : Provectus will use the University’s PDAT medical device with RB-PDT for treating bacterial and parasitic infections of the eye.
Product Name : RB-PDT
Product Type : Miscellaneous
Upfront Cash : Undisclosed
March 27, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Difluprednate Ophthalmic Emulsion,may result in posterior subcapsular cataract formation; increase the hazard of secondary ocular infections, and delay healing with the increase in the incidence of bleb formation.
Lead Product(s): Difluprednate,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Difluprednate-Generic
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 19, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Difluprednate,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Amneal Receives Approval for Difluprednate Ophthalmic Emulsion
Details : Difluprednate Ophthalmic Emulsion,may result in posterior subcapsular cataract formation; increase the hazard of secondary ocular infections, and delay healing with the increase in the incidence of bleb formation.
Product Name : Difluprednate-Generic
Product Type : Steroid
Upfront Cash : Inapplicable
November 19, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Cipla’s Difluprednate Ophthalmic Emulsion 0.05% is AB-rated generic therapeutic equivalent version of Novartis Pharmaceutical Corporation’s Durezol®.
Lead Product(s): Difluprednate,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Difluprednate-Generic
Study Phase: Approved FDFProduct Type: Steroid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 12, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Difluprednate,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Cipla’s Difluprednate Ophthalmic Emulsion 0.05% is AB-rated generic therapeutic equivalent version of Novartis Pharmaceutical Corporation’s Durezol®.
Product Name : Difluprednate-Generic
Product Type : Steroid
Upfront Cash : Inapplicable
August 12, 2021

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Difluprednate is a Steroid drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cataract.
Lead Product(s): Difluprednate,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Steroid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 17, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Difluprednate,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Difluprednate is a Steroid drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cataract.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
November 17, 2020

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Difluprednate is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cataract.
Lead Product(s): Difluprednate,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Steroid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 03, 2018

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Difluprednate,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Difluprednate is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cataract.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
October 03, 2018

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Difluprednate is a Steroid drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dry Eye Syndromes.
Lead Product(s): Difluprednate,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Steroid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 13, 2011

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Difluprednate,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Anti-Inflammatory Treatment in Dry Eye Patients
Details : Difluprednate is a Steroid drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Dry Eye Syndromes.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
January 13, 2011

Details:
Difluprednate is a Steroid drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cataract.
Lead Product(s): Difluprednate,Prednisolone Acetate
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Steroid
Sponsor: Sirion Therapeutics, Inc. | Alcon Inc | Parsons Medical Communications
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 19, 2010

Lead Product(s) : Difluprednate,Prednisolone Acetate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Sirion Therapeutics, Inc. | Alcon Inc | Parsons Medical Communications
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Difluprednate is a Steroid drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Cataract.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
November 19, 2010

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Difluprednate is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Uveitis, Anterior.
Lead Product(s): Difluprednate,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Steroid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 15, 2010

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Difluprednate,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis
Details : Difluprednate is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Uveitis, Anterior.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
September 15, 2010

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Difluprednate is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cataract.
Lead Product(s): Difluprednate,Inapplicable
Therapeutic Area: Ophthalmology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Steroid
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 14, 2010

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Difluprednate,Inapplicable
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery
Details : Difluprednate is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Cataract.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
May 14, 2010

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
ABOUT THIS PAGE
55
PharmaCompass offers a list of Difluprednate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Difluprednate manufacturer or Difluprednate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Difluprednate manufacturer or Difluprednate supplier.
PharmaCompass also assists you with knowing the Difluprednate API Price utilized in the formulation of products. Difluprednate API Price is not always fixed or binding as the Difluprednate Price is obtained through a variety of data sources. The Difluprednate Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Difluprednate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Difluprednate, including repackagers and relabelers. The FDA regulates Difluprednate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Difluprednate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Difluprednate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Difluprednate supplier is an individual or a company that provides Difluprednate active pharmaceutical ingredient (API) or Difluprednate finished formulations upon request. The Difluprednate suppliers may include Difluprednate API manufacturers, exporters, distributors and traders.
click here to find a list of Difluprednate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Difluprednate DMF (Drug Master File) is a document detailing the whole manufacturing process of Difluprednate active pharmaceutical ingredient (API) in detail. Different forms of Difluprednate DMFs exist exist since differing nations have different regulations, such as Difluprednate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Difluprednate DMF submitted to regulatory agencies in the US is known as a USDMF. Difluprednate USDMF includes data on Difluprednate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Difluprednate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Difluprednate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Difluprednate Drug Master File in Japan (Difluprednate JDMF) empowers Difluprednate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Difluprednate JDMF during the approval evaluation for pharmaceutical products. At the time of Difluprednate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Difluprednate suppliers with JDMF on PharmaCompass.
A Difluprednate written confirmation (Difluprednate WC) is an official document issued by a regulatory agency to a Difluprednate manufacturer, verifying that the manufacturing facility of a Difluprednate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Difluprednate APIs or Difluprednate finished pharmaceutical products to another nation, regulatory agencies frequently require a Difluprednate WC (written confirmation) as part of the regulatory process.
click here to find a list of Difluprednate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Difluprednate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Difluprednate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Difluprednate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Difluprednate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Difluprednate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Difluprednate suppliers with NDC on PharmaCompass.
Difluprednate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Difluprednate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Difluprednate GMP manufacturer or Difluprednate GMP API supplier for your needs.
A Difluprednate CoA (Certificate of Analysis) is a formal document that attests to Difluprednate's compliance with Difluprednate specifications and serves as a tool for batch-level quality control.
Difluprednate CoA mostly includes findings from lab analyses of a specific batch. For each Difluprednate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Difluprednate may be tested according to a variety of international standards, such as European Pharmacopoeia (Difluprednate EP), Difluprednate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Difluprednate USP).
Contact Us!